NCT00728390 2024-04-22A Safety And Efficacy Study Of The Combination Of Oral PF-00299804 And Intravenous CP-751,871 Given Every 3 WeeksPfizerPhase 1 Completed74 enrolled
NCT04511533 2024-04-05Dacomitinib for Treatment of Patients in India With Metastatic Non Small Cell Lung Cancer With EGFR Activating MutationsPfizerPhase 4 Completed101 enrolled 11 charts
NCT01774721 2023-11-14ARCHER1050: A Study of Dacomitinib vs. Gefitinib in 1st-Line Treatment Of Advanced NSCLC.PfizerPhase 3 Completed452 enrolled 35 charts 1 FDA
NCT01920061 2022-09-13A Study Of PF-05212384 In Combination With Other Anti-Tumor Agents and in Combination With Cisplatin in Patients With Triple Negative Breast Cancer in an Expansion Arm (TNBC)PfizerPhase 1 Completed110 enrolled 80 charts
NCT00768664 2021-02-09Open-Label Trial Of Oral PF-00299804 By Continuous Dosing In Patients With Recurrent Or Metastatic Head And Neck Squamous Cell CancerPfizerPhase 2 Completed69 enrolled 18 charts
NCT00548093 2019-05-21PF-00299804 As A Single Agent, In Patients With Advanced Non-Small Cell Lung Cancer Who Have Failed Chemotherapy And ErlotinibPfizerPhase 2 Completed66 enrolled 19 charts
NCT00818441 2019-01-08Dacomitinib (PF-00299804) As A Single Oral Agent In Selected Patients With Adenocarcinoma Of The LungPfizerPhase 2 Completed119 enrolled 12 charts
NCT00728468 2017-08-02A Study To Test The Impact Of PF- 00299804 On How The Body Handles Dextromethorphan In Cancer PatientsPfizerPhase 1 Completed16 enrolled 19 charts
NCT00769067 2015-10-07A Randomized Trial Of PF-00299804 Taken Orally Versus Erlotinib Taken Orally For Treatment Of Advanced Non-Small Cell Lung Cancer That Has Progressed After One Or Two Prior Chemotherapy RegimenPfizerPhase 2 Completed188 enrolled 14 charts
NCT00783328 2011-06-27A Study Of PF-00299804 In Patients In Japan With Advanced Malignant Solid TumorsPfizerPhase 1 Completed13 enrolled